Drugs / general fluid concentrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03223701 | Sep 2017 → Sep 2018 | intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis | Seton Healthcare Family | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | general fluid concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03223701 ↗ |
| Known as | GFC | “The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid...” NCT03223701 ↗ |
| Route | Other | “in the interbody space of a TLIF” NCT03223701 ↗ |